Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.

The Journal of biological chemistry - 23 May 2014

Campos-Salinas Jenny, Cavazzuti Antonio, O'Valle Francisco, Forte-Lago Irene, Caro Marta, Beverley Stephen M, Delgado Mario, Gonzalez-Rey Elena

Abstract excerpt

Vasoactive intestinal peptide (VIP) is an anti-inflammatory neuropeptide recently identified as a potential antimicrobial peptide. To overcome the metabolic limitations of VIP, we modified the native peptide sequence and generated two stable synthetic analogues (VIP51 and VIP51(6-30)) with better antimicrobial profiles. Herein we investigate the effects of both VIP analogues on cell viability, membrane integrity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gram-Negative Bacteria
Share to Gram-Positive Bacteria

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Leishmania major

Share to Leishmaniasis, Cutaneous

Share to Microbial Viability

Share to Sepsis

Share to Vasoactive Intestinal Peptide

Source

Open in PubMed Open full text

Identifiers

PMID: 24706753
DOI: 10.1074/jbc.M114.560573
PMCID: PMC4031515

Genes

VIP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic efficacy of stable analogues of vasoactive intestinal peptide against pathogens.PMID 24706753Read ↗

Novel Antimicrobial Peptides from a Cecropin-Like Region of Heteroscorpine-1 from Heterometrus laoticus Venom with Membrane Disruption Activity.Semantic proximity Read ↗

Mechanism-driven screening of membrane-targeting and pore-forming antimicrobial peptidesSemantic proximity Read ↗

Structure-based design of an antibacterial peptide from the Myotoxin II sequence, evaluating its effectiveness against Gram-negative bacteria and its safetySemantic proximity Read ↗

Unveiling novel scallop-derived antimicrobial peptides targeting host-associated vibrios for sustainable pathogen control in aquacultureSemantic proximity Read ↗

Antimicrobial and anti-inflammatory activities of three chensinin-1 peptides containing mutation of glycine and histidine residues.Semantic proximity Read ↗

Rapid Recovery from COVID-19 Respiratory Failure with Comorbidity in 21 Patients Treated with Vasoactive Intestinal PeptideSemantic proximity Read ↗

Viperin Reveals Its True FunctionSemantic proximity Read ↗

Vasoactive intestinal peptide (VIP) prevents killing of virulent and phoP mutant Salmonella typhimurium by inhibiting IFN-gamma stimulated NADPH oxidative pathways in murine macrophages.Semantic proximity Read ↗

Comparative Evaluation of the Antimicrobial Activity of Different Antimicrobial Peptides against a Range of Pathogenic Bacteria.Semantic proximity Read ↗

The Role of Viperin in the Innate Antiviral ResponseSemantic proximity Read ↗

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal systemSemantic proximity Read ↗

VIP modulates human macrophages phenotype via FPRL1 via activation of RhoA-GTPase and PLC pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.